Literature DB >> 17290202

Recurrence after surgical ablation for retinal angiomatous proliferation.

Chieko Shiragami1, Tomohiro Iida, Dai Nagayama, Tetsuya Baba, Fumio Shiraga.   

Abstract

PURPOSE: To report the frequency of recurrence of retinal angiomatous proliferation (RAP) lesions after surgical ablation.
METHODS: Seven eyes of seven consecutive patients with stage II RAP underwent surgical ablation of retinal feeder and draining vessels of RAP lesions. These eyes were examined with visual acuity testing, biomicroscopic slit-lamp fundus examination, fluorescein and indocyanine green angiographies, and optical coherence tomography before and after surgery.
RESULTS: Between 2 months and 13 months after surgical ablation, all 7 eyes (100%) had lesion recurrence with exudative and/or hemorrhagic manifestations such as macular edema, serous detachment of the sensory retina, or pigment epithelial detachment. Retinal feeding and draining vessels were recanalized (six eyes) or newly developed (one eye) in communication with recurrent intraretinal neovascularization.
CONCLUSIONS: After surgical ablation for stage II RAP, all seven eyes had recurrence of the RAP lesions. This treatment may be ineffective for RAP. Further study of this surgical technique is necessary before recommending it for the treatment of RAP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17290202     DOI: 10.1097/01.iae.0000224938.61915.f0

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  12 in total

1.  [Therapy of stage III retinal angiomatous proliferation. Intravitreal ranibizumab injections].

Authors:  M Maier; C Perz; J Bockmaier; N Feucht; C P Lohmann
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

2.  [Intravitreal ranibizumab for the treatment of retinal angiomatous proliferation].

Authors:  J Maaß; D Sandner; E Matthé
Journal:  Ophthalmologe       Date:  2017-06       Impact factor: 1.059

3.  One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation.

Authors:  Yukari Shirakata; Chieko Shiragami; Ayana Yamashita; Eri Nitta; Atsushi Fujiwara; Fumio Shiraga
Journal:  Jpn J Ophthalmol       Date:  2012-09-19       Impact factor: 2.447

4.  Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano; Kanako Itagaki
Journal:  Jpn J Ophthalmol       Date:  2016-01       Impact factor: 2.447

5.  Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano
Journal:  Jpn J Ophthalmol       Date:  2012-12-04       Impact factor: 2.447

6.  Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).

Authors:  Lazaros Konstantinidis; Evangelia Mameletzi; Irmela Mantel; Jean-Antoine Pournaras; Leonidas Zografos; Aude Ambresin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-04-29       Impact factor: 3.117

7.  [Anti-VEGF treatment for retinal angiomatous proliferation].

Authors:  A Wolf; D Kook; T Kreutzer; A Gandorfer; C Haritoglou; A Kampik; M Ulbig
Journal:  Ophthalmologe       Date:  2008-09       Impact factor: 1.059

8.  Retinal angiomatous proliferation associated with risk alleles of ARMS2/HTRA1 gene polymorphisms in Japanese patients.

Authors:  Yasuhiro Ohkuma; Takaaki Hayashi; Tsutomu Sakai; Akira Watanabe; Hisashi Yamada; Masakazu Akahori; Takeshi Itabashi; Takeshi Iwata; Toru Noda; Hiroshi Tsuneoka
Journal:  Clin Ophthalmol       Date:  2013-12-27

9.  Angiographic results of retinal-retinal anastomosis and retinal-choroidal anastomosis after treatments in eyes with retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano; Kanako Itagaki
Journal:  Clin Ophthalmol       Date:  2012-08-28

Review 10.  Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration.

Authors:  Paris Tranos; Athanasios Vacalis; Solon Asteriadis; Stavrenia Koukoula; Athanasios Vachtsevanos; Georgia Perganta; Ilias Georgalas
Journal:  Drug Des Devel Ther       Date:  2013-06-17       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.